Open Targets Platform On diseases and phenotypes, and how we learnt to stop worrying and ignore the distinction One of the questions that Open Targets Platform users ask is why we don't distinguish diseases from phenotypes. Ian Dunham tells us more in this blog post.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
Q&A Using CRISPR priority score to identify targets in cancer drug discovery Open Targets Q&A on the first set of CRISPR screen results in cancer for target identification and prioritisation in drug discovery.
Open Targets Platform Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Third in the series is C.
Open Targets How CRISPR will guide the way to better cancer therapies Fiona Behan tells us why she works in cancer research with Open Targets and how CRISPR/Cas9 has revolutionised the fight against cancer.
